Atea reports Q3 net loss $28.2M; plans Phase 3 MORNINGSKY amendment with new primary endpoint

Atea Pharmaceuticals, Inc.

2021-Q3 EPS reported $0.05 revenue$159,187,000

Net loss $28.2M for Q3 2021 vs $17.6M loss in Q3 2020; collaboration revenue $32.8M from Roche license.
Cash and equivalents $839.7M as of Sept 30, 2021, down from $850.1M at Dec 31, 2020.
Phase 3 MORNINGSKY amendment: primary endpoint to hospitalization/death; focus on unvaccinated high-risk; dose increased to 1,100 mg BID; data H2 2022.
New infectious virus data from Phase 2 MOONSONG show rapid viral load reduction (-0.5 log10) with AT-527 1,100 mg BID vs placebo at Day 3 in overall population.
In vitro data show AT-511 (free base of AT-527) maintains potency against variants including Delta.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.